FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Google, Blackstone Launch $5B AI Cloud Venture to Challenge Nvidia and CoreWeave 
Samsung Strike Talks Resume as South Korea Weighs Emergency Action 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
NEW YORK, Sept. 19, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased CytRx Corporation (NASDAQ:CYTR) securities between November 18, 2014 and July 11, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/cytrx-corporation. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts including: (1) that the clinical hold placed on the Phase 3 trial of aldoxorubicin for soft tissue sarcomas (“STSs”) would prevent sufficient follow-up for patients involved in the study; (2) that, as a result, nearly half of all patients would be excluded from the data since the study was disturbed by a partial clinical hold; (3) that, in response, CytRx would likely conduct a second analysis; (4) that, as such, the results of the trial could be materially affected and/or approval of aldoxorubicin for STS could be delayed; and (5) that, as a result of the foregoing, Defendants’ statements about CytRx’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in CytRx you have until September 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/cytrx-corporation.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
